Analysis of Antibiotic Therapy Accuracy and Drug Interaction in Pneumonia Inpatients at The Islamic Hospital Jakarta Cempaka Putih
Abstract
Polypharmacy may increase the risk of drug interactions affecting toxicity and therapeutic efficacy in pneumonia patients. This study aimed to analyse evaluation of pneumonia management, polypharmacy, relationship between polypharmacy and occurrence of drug-drug interactions, and relationship between drug-drug interactions and length of hospital stay of pneumonia patients. The study design used a quantitative descriptive approach with cross-sectional and retrospective data collection and a total sample of 113 samples that met the criteria. Analyses were performed using Spearman's rho correlation test to assess the association of polypharmacy with drug interactions, and the association of drug interactions with length of hospital stay. Medication accuracy was measured using PDPI (The Indonesian Lung Doctors Assosiaciation) guidelines, drug interactions using drugs.com and/or Medscape.com. Results showed 59.29% of patients were female, with the majority aged over 65 (55.65%). Most patients (91.15%) paid with BPJS, 62.61% were hospitalised for 1-5 days and 81.74% had comorbidities. Treatment accuracy in this study was 49.56%. 106 drug interactions were identified in a total of 226 cases. 66% of the interactions were pharmacodynamic with moderate severity (79%), such as the interaction between combivent and ondansetron. Mild pharmacokinetic interactions were common, especially between ranitidine and paracetamol (22 cases). There is a correlation between polypharmacy and drug…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.